AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q1 FY25 results · Apr–Jun 2024
AstraZeneca Pharma India reported revenue from operations of ₹387.52 crore (up 31.2% from Q1 FY24) and net loss of ₹11.79 crore for Q1 FY25 (Apr–Jun 2024), on a standalone basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 387.52 | 295.47 | +31.2% | 383.20 | +1.1% |
| Other income | 8.35 | 8.10 | +3.0% | 8.66 | −3.7% |
| Total income | 395.87 | 303.57 | +30.4% | 391.86 | +1.0% |
| Profit before tax | (15.16) | 71.40 | Turned loss | 54.35 | Turned loss |
| Net profit for the period | (11.79) | 53.86 | Turned loss | 39.48 | Turned loss |
| EPS, basic (₹) | (4.72) | 21.54 | Turned loss | 15.79 | Turned loss |
| Net margin (%) | -3.0 | 18.2 | 10.3 |
Standalone
- Filed with BSE
- 09 Aug 2024, 13:12 IST
- Board meeting
- 08 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE